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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as eIn this issue of the Journal, Yoshida et al. presented a report
regarding the platelet reactivity assessed with P2Y12 reaction
units (PRU) in patients with acute coronary syndrome with
essential thrombocythemia (ET) [1]. There are several previous
publications regarding cases of acute myocardial infarction
concomitant with ET [2–4]. Some suggest higher risk of thrombus
formation in patients with ET [5–7]. In general, increased platelet
cell count correlates with higher thrombogenicity mostly due to
increased probability for adhesion and cohesion of platelets
[8]. The same is true that the risk of bleeding increases in patients
with reduced platelet count unless the sizes of individual platelet
cells become bigger than normal [9]. It is important to note that
even platelet activation under blood ﬂow conditions is regulated
by platelet cell counts [10]. The mechano-biological relationship
between platelet membrane glycoprotein (GP) Iba with von
Willebrand factor (VWF) under high shear blood conditions and
platelet activation is still to be elucidated. We have to realize the
complexity of platelet function and its modiﬁcation by antiplatelet
therapy in ET patients even considering just one parameter of
increased platelet count.
Prediction of antiplatelet effects with P2Y12 inhibitor within ET
patients with the use of platelet function testing is even more
difﬁcult because of increased platelet count and functional
abnormality of platelets in ET patients. There are a few differences
in platelet function in ET patients and those without ET. The fact
that the known stimulus for increased platelet cell count of
thrombopoietin is also known as one of the potent platelet
stimulating agents [11]. Most probably, platelet cells in ET
patients should be sensitive to other stimuli such as VWF, ADP,
and so on.
In the report published by Yoshida et al., they suggested that
evaluating platelet reaction units (PRU) with the point of care
device (Verify Now, Accumetrics, San Diego, CA, USA) is helpful for
predicting the effects of dual antiplatelet therapy (DAPT) in
patients after percutaneous coronary intervention (PCI) with ET.
However, it is impossible to generalize the results with one case for
the general patient population with ET. The ‘‘Verify Now’’ they
used to measure PRU is one of the new measures for assessing the
effect of antiplatelet therapy [12]. In general, ‘‘Verify Now’’
measures ADP-induced platelet aggregation just like the old
measure of ADP-induced platelet aggregation measured by light
transmittance [13]. One critical difference from traditional ADP-
induced platelet aggregation is that another important plateletDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.03.007
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addition of prostaglandin E (PGE)-1 in ‘‘Verify Now’’ [14]. There are
numerous contradicting publications whether PRU measures are
meaningful for ‘‘personalized’’ dose adjustment of P2Y12 inhibitors
such as clopidogrel or not [12,15,16]. One of the largest hypothesis-
testing clinical trials demonstrated that neither efﬁcacy nor safety
was improved by dose adjustment of clopidogrel using ‘‘Verify
Now’’ [17,18]. Thus, the clinical relevance of PRU measured by
‘‘Verify Now’’ in patients treated by P2Y12 ADP antagonists is still to
be elucidated even in patients without ET [19].
A platelet is a small cell, but the exact functional regulation
mechanism in this cell is yet to be clariﬁed [8]. Unlike the concepts
used for developing ‘‘Verify Now,’’ some reports suggest a relevant
role of both P2Y1 and P2Y12 for increasing intra-cellular calcium
ion concentrations [20]. PRU may reﬂect P2Y12 inhibition more
closely than ADP-induced platelet aggregation, but this hypothesis
is still to be elucidated. Although ‘‘Verify Now’’ is widely used for
assessing the efﬁcacy of P2Y12 inhibitors, we have to be aware that
all the results might just be an interesting artifact and not relevant
to clinical outcomes.
A previous publication suggests that platelet cells in patients
with ET are resistant to stimulation by catecholamines [21]. Plate-
let cells express a2-receptor for stimulation by catecholamines.
Platelet cells become more sensitive to other stimulation when a2-
receptors are stimulated by small amounts of catecholamine
[22]. Increased number of platelets with heterogeneous char-
acteristics of sensitivity or resistance to ADP stimulation in ET
might result either in apparently ‘‘resistant’’ or ‘‘sensitive’’ to any
stimulations in mass of platelet cells as shown in Fig. 1. ‘‘Verify
Now’’ assesses platelet function as a ‘‘mass of platelet cells’’ and not
as individual ones. Reaction as a ‘‘mass of cells’’ may not be the
same as ‘‘individual platelets’’. One typical example is that the
intracellular calcium ion concentrations of individual platelet cells
go up and down over time [20], while it looks like an increased
monophasic response in a ‘‘mass of platelet cells’’ [23]. Platelet
cells in vivo are hugely heterogeneous in size, number of
expressing proteins, and reaction to various stimuli in individual
cells [10]. A greater inter-platelet heterogeneity in patients with ET
might be the reason to show apparently different behavior against
ADP receptor stimulation as shown in Fig. 1.
Finally, the use of ‘‘point of care devices’’ to individualize
antithrombotic therapies remains challenging. Even though some
trials suggest correlation of PRU and thrombotic event rates, no
study has demonstrated the beneﬁt of personalized adjustment of
the dose of P2Y12 ADP receptor inhibitors by PRU. All results using
‘‘Verify Now’’ might just be an interesting artifact. If we really want reserved.
Fig. 1.
Why the speculation based upon the results of ‘‘VerifyNow’’ for the mechanism of platelet activation and/or its inhibition by drug intervention is problematic?
Increased number of platelet cells in ET may inﬂuence the apparent response of platelets in ‘‘mass’’. We have to be careful for assessing the effects of antiplatelet
agents with the use of point of care devices just measuring the reaction of ‘‘mass of cells’’.
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P2Y12 ADP receptor inhibitors, quantitative understanding of the
relationship between the dose taken as drugs, the actual P2Y12
ADP receptor blockage (e.g. number of receptors blocked/number
of available receptors) [8], and the quantiﬁcation of the
heterogeneity between actual P2Y12 ADP receptor blockage and
cell response (such as number of GPIIb/IIIa proteins changed to
activated form, number of dense granules released, number of
ﬁbrinogen molecules released from activated platelet, etc.) is
necessary. An evidence-based approach emphasizing the impor-
tance of randomized control trials (RCTs) might still have some
role for personalized medicine by selecting a small high-risk
population who needs new therapies [24]. For the rare case such
as ET, a ‘‘bottom up’’ approach with constructive logic from exact
understanding of the detailed mechanism of platelet cells is
essentially important.
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